REGN Company Profile and Key Details

Q: Who are the executives of REGN?

Mr. Joseph J. LaRosaExecutive Vice President, Gen. Counsel & Sec.Mr. Robert E. Landry Jr.Executive Vice President of Fin. & Chief Financial OfficerDr. Andrew J. Murphy Ph.D.Executive Vice President of ResearchMs. Patrice GiloolySenior Vice President of Quality Assurance & OperationsMr. Christopher R. FenimoreSenior Vice President, Head of Accounting & ControllerMr. Bob McCowanSenior Vice President of IT & Chief Information OfficerMr. Daniel P. Van PlewExecutive Vice President and GM of Industrial Operations & Product SupplyMr. Gerald UnderwoodSenior Vice President of Technical OperationsDr. Leonard S. Schleifer M.D., Ph.D.Co-Founder, Pres, Chief Executive Officer & DirectorDr. George D. Yancopoulos M.D., Ph.D.Co-Founder, Pres, Chief Scientific Officer & Co-ChairmanMs. Marion E. McCourtExecutive Vice President of Commercial

NASDAQ : REGN

Regeneron Pharmaceuticals

$766.63

-8.43-1.09%

At Close 4:00 PM

50.48

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Regeneron Pharmaceuticals, Inc. (REGN) stock declined over -1.09%, trading at $766.63 on NASDAQ, down from the previous close of $775.06. The stock opened at $782.05, fluctuating between $760.00 and $790.00 in the recent session.

Stock Snapshot

775.06

Prev. Close

79.18B

Market Cap

760

Day Low

18.12

P/E Ratio

42.32

EPS (TTM)

35.77

Cash Flow per Share

782.05

Open

103.28M

Number of Shares

790

Day High

93.97%

Free Float in %

243.65

Book Value

975.12K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 05, 2026	777.83	790.00	760.00	766.63	974.72K
Feb 04, 2026	765.80	779.78	765.21	775.06	951.72K
Feb 03, 2026	745.53	773.72	742.74	759.18	767.21K
Feb 02, 2026	732.92	763.56	731.51	755.02	692.59K
Jan 30, 2026	753.96	774.37	735.61	741.45	1.31M
Jan 29, 2026	755.73	755.73	742.80	749.44	920.01K
Jan 28, 2026	765.15	766.99	747.57	751.13	824.47K
Jan 27, 2026	762.47	776.25	761.50	771.25	644.28K
Jan 26, 2026	750.09	767.30	750.09	762.65	933.17K
Jan 23, 2026	757.31	762.00	747.30	753.55	665.68K
Jan 22, 2026	750.34	765.00	747.37	755.51	760.03K
Jan 21, 2026	736.71	750.00	735.00	749.33	787.13K
Jan 20, 2026	729.40	737.87	718.38	733.78	784.77K
Jan 16, 2026	749.09	749.09	726.43	733.04	1.68M
Jan 15, 2026	754.85	756.50	737.00	741.92	865.52K
Jan 14, 2026	760.58	766.64	753.01	754.14	668.78K
Jan 13, 2026	765.16	765.99	743.94	758.91	946.39K
Jan 12, 2026	810.00	811.09	765.08	768.00	1.32M
Jan 09, 2026	802.97	821.11	790.88	796.55	711.53K
Jan 08, 2026	805.81	816.99	800.68	801.01	1.05M

Contact Details

Tarrytown, NY 10591-6707

United States

https://www.regeneron.com 914 847 7000

About Company

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Stock Peers

ARGX

-30.56-3.59%

argenx SE$820.31 UTHR

-3.66-0.76%

United Therapeutics Corporation$478.93 MDGL

-15.19-3.17%

Madrigal Pharmaceuticals, Inc.$463.42 VRTX

-11.71-2.49%

Vertex Pharmaceuticals Incorporated$458.81 ALNY

-20.72-5.89%

Alnylam Pharmaceuticals, Inc.$331.24 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

2.28+0.75%

Praxis Precision Medicines, Inc.$305.62 KRYS

-1.49-0.55%

Krystal Biotech, Inc.$267.64 SGEN

-0.16-0.07%

Seagen Inc.$228.74 CDTX

Cidara Therapeutics, Inc.$221.38

Company Overview

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) closed at $766.63 USD, losing -$8.43 (-1.09%) from the previous close of $775.06. The stock is currently mid-range between its 52-week high and low $476.49 and $821.11. With a market capitalization of about $79.18 billion, Regeneron Pharmaceuticals, Inc. is classified as a large-cap and shows lower-than-market volatility (beta ~0.41). Key stats such as the average daily volume over the past year has been around 966.82 thousand shares, in line with its 52-week average. Headquartered in Tarrytown, NY, Regeneron Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Leonard S. Schleifer, the company employs approximately 15,158 people and listed since April 02, 1991. Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 1.02%, SMA50 1.11%, SMA200 23.13%). The stock’s 14-day RSI is 53.54 (neutral), while the ATR of 22.61 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -6.63% below its high and over 60.89% above its low. Average 10-day trading volume of 891.25 thousand shares is in line with the 3-month average of 942.74 thousand, indicating normal recent market interest.

Valuation Metrics

Regeneron Pharmaceuticals, Inc. trades at a P/E ratio of 17.67, slightly below the S&P 500 average, with a price-to-sales ratio of 5.57 and a price-to-book ratio of 2.55 suggesting the stock is closer to book value. The P/FCF stands at 25.29, also above market averages.

Dividend & Fair Value

Regeneron Pharmaceuticals, Inc. last paid a dividend of 3.52 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.17 thousand. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Regeneron Pharmaceuticals, Inc. generated EPS of $41.56 over the past year. Five-year average earnings growth is 6.33%. Wall Street analysts project EPS growth of 10.84% annually over the next five years. The latest quarter delivered EPS of $11.83. The next quarter is forecast at $9.15. Next year's EPS is expected at $3.06. Analyst sentiment is bullish. Analyst rating data shows there are 13 Strong Buy ratings, 15 Buy ratings, 14 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $1.06 thousand to $580.00. The high target offers 38.27% upside. The low target suggests -24.34% downside. The mean target is $782.47. This offers 2.07% upside. Regeneron Pharmaceuticals, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended October 28, 2025, missed forecasts by 22.59%. The prior quarter beat by 52.91%. Over the last six quarters, Apple has recorded several small beats. These include 17.63% in August 01, 2024.

Shareholding & Insider Activity

Regeneron Pharmaceuticals, Inc. has 104.17 million shares outstanding. The public float is 97.89 million shares, elevated short interest at 2.34% of float. This equals 2.35 million shares. The short ratio is 2.36 days. Institutional investors hold 91.99% of the float. Insiders own 1.93%. YANCOPOULOS GEORGE holds 786.38 thousand shares, STAHL NEIL has 51.00 thousand shares and MURPHY ANDREW J has 48.31 thousand shares. Over the past six months, insider transactions show net selling. They sold 3.40 thousand shares across 4 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Regeneron Pharmaceuticals generated $14.20B in revenue, or $123.39 per share. Gross margin was 93.07%, operating margin 28.10%, and net profit margin 31.07%. Returns are healthy, with ROA at 13.34% and ROE at 16.99%.
On valuation metrics, Regeneron Pharmaceuticals trades at a P/E of 17.67, P/S of 5.57 and P/B of 2.55. The current ratio is 4.77 and quick ratio is 4.22. Operationally, the company’s inventory turnover is 0.62 and cash conversion cycle is -342.06 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.09, supported by a cash flow-to-debt ratio of 1.41.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2024, Regeneron Pharmaceuticals posted revenue of $14.20B, down slightly from $13.12B in the prior quarter. Gross profit was $13.22B (margin 93.07%). Operating income was $3.99B (margin 28.1%). Net income was$4.41B (EPS $40.90).
The company ended the quarter with $10.84B in cash and short-term investments, a total debt of $2.70B, and net debt of - $27.10M. Total assets were $33.08B, with equity of $25.97B. Financials further reflected stability, with operating cash flow of $4.59B, free cash flow of $3.67B, and capital expenditures of - $926.40M.

Price Forecast & Outlook

Our AI price prediction model suggests that Regeneron Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.82%, with price expected at $752.65 by February 18, 2026, within a range of $733.96 to $771.04 3-Month Outlook: Projected rise of 1.75%, reaching $780.06 by May 05, 2026, with a range of $723.80 to $834.21. 1-Year Outlook: Projected loss of -5.34%, with price at $725.69 by February 04, 2027, within a range of $668.76 to $787.74.

Key Takeaways

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares are flat -4.93% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Regeneron Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of 17.67. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $876.05, suggesting 14.27% upside. Our AI forecast model points to short-term weakness (-1.82% over two weeks), a medium-term rise (1.75% over three months), and a longer-term loss (-5.34% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Regeneron Pharmaceuticals, Inc. (REGN) stock price?

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stock price is $766.63 in the last trading session. During the trading session, REGN stock reached the peak price of $790.00 while $760.00 was the lowest point it dropped to. The percentage change in REGN stock occurred in the recent session was -1.09% while the dollar amount for the price change in REGN stock was - $8.43.

REGN's industry and sector of operation?

The NASDAQ listed REGN is part of Biotechnology industry that operates in the broader Healthcare sector. Regeneron Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of REGN?

Mr. Joseph J. LaRosa
Executive Vice President, Gen. Counsel & Sec.
Mr. Robert E. Landry Jr.
Executive Vice President of Fin. & Chief Financial Officer
Dr. Andrew J. Murphy Ph.D.
Executive Vice President of Research
Ms. Patrice Gilooly
Senior Vice President of Quality Assurance & Operations
Mr. Christopher R. Fenimore
Senior Vice President, Head of Accounting & Controller
Mr. Bob McCowan
Senior Vice President of IT & Chief Information Officer
Mr. Daniel P. Van Plew
Executive Vice President and GM of Industrial Operations & Product Supply
Mr. Gerald Underwood
Senior Vice President of Technical Operations
Dr. Leonard S. Schleifer M.D., Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
Dr. George D. Yancopoulos M.D., Ph.D.
Co-Founder, Pres, Chief Scientific Officer & Co-Chairman
Ms. Marion E. McCourt
Executive Vice President of Commercial

How REGN did perform over past 52-week?

REGN's closing price is 60.89% higher than its 52-week low of $476.49 where as its distance from 52-week high of $821.11 is -6.63%.

How many employees does REGN have?

Number of REGN employees currently stands at 15,158.

Link for REGN official website?

Official Website of REGN is: https://www.regeneron.com

How do I contact REGN?

REGN could be contacted at phone 914 847 7000 and can also be accessed through its website. REGN operates from 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, United States.

How many shares of REGN are traded daily?

REGN stock volume for the day was 975.12K shares. The average number of REGN shares traded daily for last 3 months was 966.82K.

What is the market cap of REGN currently?

The market value of REGN currently stands at $79.18B with its latest stock price at $766.63 and 103.28M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	15158
Beta	0.39
Sales or Revenue	$14.20B
5Y Sales Change%	1.103%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

REGN Company Profile and Key Details

Regeneron Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways